CAJ | 학술논문

目的总结拉帕替尼(lapatinib)治疗HER-2阳性晚期乳腺癌的临床疗效及不良反应.方法选取2007年12月-2011年12月于我科使用拉帕替尼治疗的23例患者临床资料,观察疾病进展时间、有效率、临床获益率及不良反应.结果总体有效率65.2%,临床获益率86.9%,中位至疾病进展时间11.9个月.不良反应为腹泻、手足综合征及口腔黏膜炎,未出现3~4级的不良反应.结论拉帕替尼是HER-2阳性晚期乳腺癌的一种有效且具有良好耐受性的分子靶向药物.
목적총결랍파체니(lapatinib)치료HER-2양성만기유선암적림상료효급불량반응.방법선취2007년12월-2011년12월우아과사용랍파체니치료적23례환자림상자료,관찰질병진전시간、유효솔、림상획익솔급불량반응.결과총체유효솔65.2%,림상획익솔86.9%,중위지질병진전시간11.9개월.불량반응위복사、수족종합정급구강점막염,미출현3~4급적불량반응.결론랍파체니시HER-2양성만기유선암적일충유효차구유량호내수성적분자파향약물.
Objective To study the therapeutic effect of lapatinib on HER-2 positive advanced breast cancer and its toxic and side effect. Methods Clinical data about 23 patients with HER-2 positive advanced breast cancer who received lapatinib treatment in our hospital from December 2007 to December 2011 were analyzed. Time of disease progress, effective therapeutic rate, beneficial clinical rate, and toxic and side effect were observed. Results The total effective rate and beneficial clinical rate of lapatinib was 65.2%and 86.9%, respectively, for HER-2 positive advanced breast cancer. The time from median to disease progress was 11.9 months. The main toxic reactions to lapatinib were diarrhea, hand-foot syndrome and oral mucositis. No grades 3-4 toxics reactions occurred. Conclusion Lapatinib is an effective and well-tolerated molecular targeting drug for HER-2 positive advanced breast cancer.